Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
TCR Cell Therapy
Adoptive T-cell immunotherapy is an important cancer treatment strategy. In particular, the emergence of T-cell receptor (TCR) T cells presents great promise for more precise and personalized cancer immunotherapies. TCR-T cells can potentially treat broad patient populations suffering from various types of cancer, especially solid cancers. At present, many efforts are being made to improve the efficacy and clinical applicability of TCR T therapy.
Fig.1 Schematic overview of endogenous and genetically modified TCR complex.1
TCR Cell Products
Based on state-of-the-art TCR development platforms and advanced technologies, Creative Biolabs is dedicated to providing a wide range of TCR-T services. With years of experience in cell therapy manufacturing, we are committed to the delivery of the broad industry knowledge and experience to support your therapeutic development. We use our TCR platform to screen, identify, characterize, and optimize TCRs to generate high-affinity TCRs. Our scientists will choose to generate a stable TCR-T cell line where specific TCR genes are integrated into the host genome. Besides, we provide a variety of in vitro and in vivo assays to evaluate the TCR-T cell functions.
TCR-based T-cell therapies have shown effective and long-lasting tumor control. We provide a wide range of TCR-Jurkat cell products with various tumor antigen targeting. In addition to introducing cancer-reactive TCRs into T-cells, NK cells are another potential target cell for TCR constructs. Providing unmatched expertise in TCR cell development and manufacturing, our team of scientific experts is here to advance the success of the researchers we work with.
Reference
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
